

# ANNUAL REPORT AND ACCOUNTS

2022-2023



**THE  
BRAIN  
TUMOUR  
CHARITY**





# CHAIR'S REPORT

**Looking back at 2022-3, as with most years at The Brain Tumour Charity, it is no mean feat to distill what has been achieved over the past twelve months into just a few paragraphs.**

Most excitingly, The Charity returned to significant research grant rounds after sadly needing to reduce these during the pandemic. An impressive £6.3 million was committed to research in the financial year to 31 March 2023, including to our five new Future Leaders (see page 15), and we expect to exceed this level of grants in our next financial year.

We saw a record year of income at £12.7 million, which represents growth of 11% on 2021/22. I'd like to extend much gratitude to the marvellous team at The Charity who have ensured its vital work has continued to shine during this period, as well as to all those incredible people in our community who continue to support us and enable us to achieve what you will read about in the following pages – we truly couldn't do it without you!

I was thrilled to attend and speak at The Twilight Walk in March 2023, during Brain Tumour Awareness Month. We came together with the community for our first Charity-organised, in-person walk since the pandemic, taking strides past London's landmarks for the first time. At the same time, people affected by brain tumours held their own walks up and down the country. This was an incredibly inspiring month of awareness-raising and fundraising, and you can read more about it on page 23.

This year marks the end of our interim strategy, *Leaning In*, and the beginning of our new seven-year strategy for change, *Living Longer and Better: 2023-2030*, which you can find out more about over the next few pages. Co-created with our community and consisting of bold commitments to accelerate cures for all

brain tumours, drive the best lifelong care and raise our global voices, I'm confident that this strategy will propel powerful change for everyone diagnosed with a brain tumour and their loved ones.

I'd like to thank our amazing Trustees for all the dedicated and generous hard work they give in support of The Charity. I am fortunate indeed to have the help of people with a wide range of experience and skills which, working together, help make it such an outstanding and successful organisation. Particular thanks go to our former trustees Graham Norton and Graham Lindsay for so expertly steering The Charity in 2022-23 as our Interim CEO, and Interim Deputy CEO as we conducted our search for a new permanent CEO. Thanks also to Beth Worrall, for temporarily stepping down as a Trustee and so adeptly leading The Charity as Interim CEO from April to June 2023.

We've been looking for someone with very special, almost unique, qualities to lead The Charity into the future, and I'm pleased to say we believe we have now found that person. Dr Michele Afif's wide professional experience in the medical, legal and charity sectors is almost unparalleled and her empathetic style fits well with the caring and understanding culture we promote amongst our staff and within the brain tumour community we serve. We're delighted to have Michele join us and take The Charity onward and upward as we move forward with our new strategy. You'll hear from Michele on page 6.

We can only achieve everything we do by working together. So if you'd like to get involved, whether by raising awareness, raising funds, campaigning for change, volunteering, sharing your story or anything else, please do visit [thebraintumourcharity.org/get-involved](https://thebraintumourcharity.org/get-involved)

Thank you,

**Jack Morris CBE**  
Chair of Trustees

## CONTENTS


|  |           |
|--|-----------|
| <b>Report of the Trustees</b>                  | <b>3</b>  |
| a. Strategic Report                            | 12        |
| b. Statement of the Trustees' responsibilities | 36        |
| <b>Independent auditor's report</b>            | <b>37</b> |
| <b>Statement of financial activities</b>       | <b>40</b> |
| <b>Balance sheet</b>                           | <b>41</b> |
| <b>Cash flow statement</b>                     | <b>42</b> |



# LIVING LONGER AND BETTER: OUR NEW CO-CREATED STRATEGY FOR 2023-2030

Brain tumours kill more children and adults under 40 than any other cancer. They reduce life expectancy by an average of 35 years globally and 27 years in the UK – far more than any other cancer or significant disease. And in the UK, just 13% of people survive brain cancer for more than five years.

## OUR STRATEGY AT A GLANCE



This is not a small disease – it's a global community of over one million people, 88,000 of them living in the UK. These people, their families and carers deserve better than the prognoses they currently face. They urgently need cures and to live longer and better.

Until recently, survival rates and treatments had barely improved for a generation. But that's now changing, with research funding tripling in the last decade. It's crucial that, together, we not only sustain but accelerate this progress!

People affected by brain tumours told us they desperately need more effective treatments and prompter diagnoses. They need more hope and less fear. They need to be treated holistically, as people and not just patients, to feel connected and powerful, and to make choices about what matters to them.

Ultimately, they need cures, they need better lifelong care, and their voices must be heard globally.

That's why we came together with the community to co-create *Living Longer and Better: 2023-2030* – our new seven-year strategy for change. This is how we're going to not only build a better future but improve lives today. And we can't do it alone. We're asking you to join us as we accelerate cures and forge ahead towards a world where people diagnosed with a brain tumour live longer and better.

*Living Longer and Better* was created by and for the brain tumour community. It's a bold leap forward in ambition and collaboration, and that boldness comes from the strength and power in the community. It's their experiences that form the lynchpin of this strategy and their voices that are steering our future.

To co-create this strategy, we collaborated with 1,200 people from across the community, the output of which has resulted in a transformative step change in taking on brain tumours – a brave blueprint for a better future that's laser-focused to create the most impact.

It sets out our vision of a world where people affected by brain tumours live longer and better. It sets out our goals – to double survival and halve the harm brain tumours have on quality of life. And it sets out the commitments we must drive forward as a collaborative ecosystem, both in the UK and globally.

Built around three core commitments –

- accelerating cures for all brain tumours
- driving the best lifelong care, and
- raising our global voices

– we know this strategy gives us the best chance of reaching our shared vision. We recognise and embrace that we're part of a global ecosystem of people and organisations united by a common purpose. We haven't created this strategy alone and we're not going to deliver it alone – we must work together internationally and go further, faster to achieve our goals.

Now that we've experienced the power of co-creation, we're resolved to collaborate in everything we do. We commit and look forward to working alongside all of *you*, together striding forward towards cures for all brain tumours and a world where people diagnosed live longer and better.



# CEO'S REPORT

It was my great privilege to take up the CEO role at The Brain Tumour Charity in July 2023 and join such a capable and dedicated team, relentless in their search for a cure and tireless in their support for all those who've experienced this most difficult of diagnoses.

A doctor by training and background, my experience working in paediatric haematology and oncology meant I saw first hand the cruelties associated with brain tumours. With so many advances elsewhere in cancer treatment, there's an urgent need to see similar improvements for the brain tumour community.

This year, the team and all our supporters have gone above and beyond to make amazing things happen. We are united in the pursuit of our shared goals, which continue to drive us towards a world where people with brain tumours live longer and better lives.

In addition to the resumption of our research grant programme, and alongside reaching a record income, incredible achievements this year include:

- growth in our **online support community memberships** to more than 28,000 memberships and supporting over 9,000 people one-on-one (7% more than the previous year)
- the launch of our new **counselling support service** which helped 261 people, the majority of whom reported a significant and positive impact on their wellbeing – the basis on which we will continue to expand this service

- publishing our **Brain Tumours: Fighting for Faster Diagnosis** report which details eight policy recommendations that we believe would enable faster diagnosis and, in turn, improve experiences and quality of care

- launching our **Better Safe Than Tumour Campaign** which has so far resulted in over 32,000 people using our interactive online signs and symptoms tracker. We have also had the opportunity to train over 4,000 healthcare professionals in recognising the signs and symptoms that may be indicative of a brain tumour.

Even as so much has been achieved, there is undoubtedly much more to do. Over the course of this year we collaborated with 1,200 people, bringing their voices together to create the community's mandate for change. This mandate forms the lynchpin of our new strategy, *Living Longer and Better: 2023-2030*, which will guide The Charity's activities over the next seven years.

I look forward to working alongside this amazing community to ensure The Brain Tumour Charity's hugely important work continues unabated in the drive to deliver its unashamedly ambitious goals. We are committed to doubling survival and halving the harm that brain tumours have on quality of life by 2030, and we know that with your continued support, together, we will achieve these goals.

Thank you,

**Dr Michele Afif**  
CEO

# OUR GOALS AND VALUES

## OUR GOALS

Our vision is for a world where brain tumours are defeated and our goals are our blueprint for getting there. Simply put, if something doesn't help us achieve one of these goals, we know that it's not the right direction for us.

We've set ourselves goals that are unashamedly ambitious as this is the only way we'll see a real and lasting difference. We want to:

- **double survival in the UK**
- **halve the harm that brain tumours have on quality of life in the UK**

## OUR VALUES

Our values underpin everything that we do, they define what we believe and guide our actions every day.

The way we work is always:

### PIONEERING

We're relentless and courageous in the pursuit of our vision, seeking new ways to make a difference.

### PASSIONATE

People are at the heart of everything we do. We're passionate about finding a cure and ensuring everyone affected by a brain tumour has the highest quality of life and chance of survival.

### COLLABORATIVE

We'll only achieve our vision by building networks, partnerships and a strong community of people affected by a brain tumour. We collaborate and value everyone's contribution.

### SMART

We're focused and intelligent in our approach to defeating brain tumours.

# EQUALITY, DIVERSITY AND INCLUSION (EDI)

**We continue to undertake significant work to further our Equality, Diversity and Inclusion (EDI) agenda to ensure we can meet diverse needs both internally and externally to the community and our stakeholders**

## ACCELERATING CURES FOR ALL BRAIN TUMOURS

Diversity in research suffers from a number of external factors, such as access to education and university places. The Charity is contributing towards the creation of a truly diverse research environment in the following areas.

- Our Future Leaders programme aims at supporting researchers early in their career, a period where difficulty securing support can lead to brilliant minds choosing different career paths.
- We've also reshaped our Expanding Theories award. In addition to allowing early career researchers to apply for their own funding, this award is now blinded during review, minimising any unconscious bias during the process.
- We aim to maintain diversity on our Scientific Advisory Board wherever possible and actively guard against unconscious bias at each meeting.

## DRIVING THE BEST LIFELONG CARE

We're dedicated to identifying and eliminating inequalities and unmet needs in healthcare treatment and support.

- Next year we'll be evolving the Wraparound Care Standard and focusing on parts of the pathway where the greatest gaps exist.
- This year we've run Round 3 of the Adult Improving Brain Tumour Care surveys and developed our Faster Diagnosis policy paper and recommendations, which will help us drive equal access to the best care and prompt diagnoses.
- We've developed several services this year specifically to address large gaps and differences in care, including counselling (see page 19) and My Support Plan (see page 18). We're also currently working to improve access for underserved groups.

## RAISING OUR GLOBAL VOICES EDI AND OUR TEAM

EDI is a core component of everything we do in Fundraising, Marketing and Customer Experience, ensuring that our events, fundraising, website and all outward facing channels and teams are accessible.

- We work to ensure that our brand and campaigns are diverse and inclusive.
- We have audited and started to fill gaps in our story, image and video libraries.
- We work with our community to ensure community fundraising and events are accessible.
- Accessibility remains at the heart of our website – and recent developments have improved it further.
- We continue to monitor, track and evolve our vulnerable person, complaints and fundraising guidance policies, to ensure we're giving the very best experience to all in our community.
- Our growing Involvement Network of people affected by a brain tumour increasingly shapes everything we do, including co-creating our new strategy.

We strive to be a diverse and inclusive Charity because we believe it's important that we represent the community that we serve, and want everyone who works with us to have a positive experience, feel that they belong and have a voice in the things that matter most to them.

Among other projects and initiatives, we've been:

- collecting and monitoring diversity data
- celebrating cultural and religious events
- educating and training the team around EDI topics
- strengthening our EDI Champion group and EDI Trustee Committee
- creating an accessible and inclusive working environment
- establishing new organisational values which help underpin a radically inclusive approach: Community first, Collaborative, Bold, and Innovative.

# ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

## SOCIAL AND GOVERNANCE

A social ethos is intrinsic in The Charity since its purpose of existence is to serve the brain tumour community and drive change, and our values reflect this. We have comprehensive policies on matters such as anti-modern-slavery and through our Governance and Ethics committee keep under constant review our relationships and compliance to ensure the highest standards.

## REDUCING ENVIRONMENTAL IMPACT

Every team in The Charity considers what changes, big or small, they can make to reduce the environmental impact of what we do.

Examples of the specific actions we have made in the year are:

- Eco-friendly collection boxes
- Wooden medals
- Website optimisation
- Moving investments to support greener energy

Our Sustainability Champions group also meets regularly to review the actions being taken, make suggestions for improvements and keep environmental considerations at the forefront of people's work and personal life.





# OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

- relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system
- relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support
- advancing the education of the public in all areas relating to tumours of the brain and central nervous system.

## PUBLIC BENEFIT STATEMENT

The Trustees have considered the Charity Commission’s general guidance on public benefit and have taken it into account when reviewing The Charity’s aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.



## DEFEATING BRAIN TUMOURS: LEANING IN

COVID-19 had a major impact on those with brain tumours, on brain tumour care, on the pace of research and on our own resources. Our short-term strategy, *Defeating Brain Tumours: Leaning In*, was developed in order to support the community’s heightened needs through the pandemic and beyond.

In 2022-3, we were able to move on from the emergency response needed after March 2020 towards tackling some of the longer-term issues that had arisen or remained pressing – such as restarting our research funding, launching our adult early diagnosis campaign, generating and sharing the insights we needed to drive change, and providing tools for our team and the wider community to amplify our voices.

As well as retaining the four pillars (Power of Data, Best Care Everywhere, Voices for Change and Make it Count) from *Leaning In*, we added a fifth pillar, Accelerate a Cure, to reflect the restarting of our research funding.

**Accelerate a Cure** Funding research to create new knowledge and understanding, accelerating new treatments by translating breakthroughs into benefit for patients, and enhancing quality of life.

**Power of Data** Harnessing the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

**Best Care Everywhere** Driving the best care everywhere across the UK, empowering the community to access high levels of care no matter where they’re located and helping treatment centres reach the highest possible standards.

**Voices for Change** Empowering everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they’re fundraisers or change makers.

**Make it Count** Using our resources, skills and technology efficiently and effectively to make sure we maximise our impact with minimal resources.

# BETTER SAFE THAN TUMOUR

We’re not slowing down in our mission to drive down diagnosis times for brain tumours! In July 2022, we launched our **Better Safe Than Tumour** campaign to raise crucial awareness of the signs and symptoms of a brain tumour.

6M

people saw the ad on TV!

The campaign was built on all the amazing groundwork done by our previous signs and symptoms awareness campaign, HeadSmart.

But while HeadSmart focused on spreading awareness of the common signs and symptoms of a brain tumour in childhood, **Better Safe Than Tumour** also aims to raise awareness of the signs and symptoms in adults.

We also gave the campaign a brand new, attention-grabbing look and feel that gives it a closer link to The Brain Tumour Charity.

And we’ve already had an incredible impact:

- 161,000 people accessed the campaign website
- Over 32,000 people completed the signs and symptoms tracker
- 5,000 people requested a pdf download of their symptoms to take with them when consulting a healthcare professional





# STRATEGIC REPORT

## ACCELERATE A CURE

We fund research to create new knowledge and understanding, accelerate new treatments by translating breakthroughs into benefit for patients, and enhance quality of life.

### HIGHLIGHTS OF 2022/23

#### RESTARTING GROUNDBREAKING RESEARCH

This year, we restarted our research funding programme after pausing it during the COVID-19 pandemic. Much of the effort put in this year will bear fruit early in 2023-24, with applications opening this year resulting in awards being made during the next financial year.

In total during 2022-23, we were able to commit £6.3 million to new research, marking a real return from the hiatus seen due to the global downturn.

We have re-established our Expanding Theories awards – small project grants to take promising ideas and provide proof of concept data. We have also restarted our Quest for Cures awards – large programmatic awards supporting collaborative research bringing projects close to clinical testing.

# £6.3M

committed to new research

Both these rounds attracted the highest number of applications we have ever seen, possibly due to the lack of funding from many sources during the pandemic, and possibly due to the success of our

pandemic webinar series, which saw us double the number of researchers who now hear about our awards.

We also had a call for a Paediatric Clinical Trial, looking to deliver on our strategic commitment to support complex innovative design trials. We asked the community to suggest ideas for a multi-arm platform study in paediatric high grade glioma, allowing all children, teenagers and young adults with high grade gliomas access to innovative treatments based on their molecular diagnosis. We hope to be making an award in this area in the next financial year.

#### FUNDING NEW FUTURE LEADERS

While the above grants are yet to be awarded, our priority this year was ensuring our Future Leaders programme continued, and we're delighted to report that our third Postdoctoral Fellowship round has awarded grants to five aspiring leaders in neuro-oncology.

The recipients are based in the UK, Europe and the USA, and are a mix of clinician scientists and discovery scientists, whose research will create the foundations of new knowledge in the field and form the basis of their careers as they establish independent laboratories. You can read more about them on page 15.

Excitingly, we also ran the first of our second stage applications in this programme and will be making awards to our Junior Fellowships early in the 2023-24 period.

#### RENEWING EVEREST CENTRE FUNDING

Finally, we were able to support a second five-year award for the Everest Centre. Established in 2017 between researchers at the German Cancer Research Centre (DKFZ) in Heidelberg and St Bart's and UCL in London, this world-leading programme has led to real progress in understanding and treating paediatric low grade glioma, including:

- the development of molecular classification of paediatric brain tumours, meaning more accurate diagnosis and changes to treatments
- understanding of the unique growth cycle of low grade glioma and how this helps the tumours resist treatment
- novel treatments that target this phenomenon which are ready for clinical trials
- the establishment of the LOGGIC trial, supporting the progression of a molecularly targeted treatment toward approval in paediatric low grade glioma.

The renewed funding of £5 million will allow the researchers to gain a more detailed understanding of the cells in low grade brain tumours and find ways to predict which patients will benefit most from different treatment options being tested in clinical trials.

They also plan to speed up the confirmation of a specific diagnosis by using new technologies and building on their previous work. By combining this with artificial intelligence they hope to be able to make world-leading diagnostic approaches available to all children, no matter where in the world they are.

Finally, this next-stage funding will support the establishment of clinical trials, enabling the translation of these key discoveries into real-world advances in patient outcomes.



# THE POWER OF DATA

We harness the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

## HIGHLIGHTS OF 2022/23

### ESTABLISHING A DATA STRATEGY

This year we completed The Charity's data strategy and began to operationalise it. The strategy, which covers the period from 2023 to the end of 2024, outlines: (1) the data structure and technology we need, (2) plans for advancing our use of analytics, (3) a SWOT (strengths, weaknesses, opportunities and threats) analysis, (4) improvements to our data maturity and governance and (5) the data strategy roadmap.

As part of this work, we've introduced training to improve the wider Charity's skills and understanding of data, in order to build a more data-driven culture.

To support this work and to further our desire to be a data-led Charity, we've been producing a number of dashboards on a data visualisation tool called Power BI, allowing all users to easily see and utilise the data from across The Charity. We are also looking at ways that we can make some of these data available outside of the organisation, increasing the transparency of our work and providing the information for the community to support their own campaigns and messages.

### IMPROVING OUR BRIAN APP

Registered users to BRIAN continue to increase. BRIAN is our app and databank designed to support people affected by a brain tumour and provide researchers with valuable data. We've had a 33% growth in users in the last year, bringing the total to 9,796 users. Work continues to re-design the app so that it is more intuitive to use.

As part of this, with the involvement of our community, in early 2023 we completed a rapid redesign process, taking forward novel ideas to enhance the app user experience and deepen engagement, and these are being taken forward now, with plans to complete this development for a launch in the winter.

We continue to increase the data sources that support BRIAN as well as work to improve the accessibility of these data. We've agreed to work with Dr Matthew Williams at Imperial College NHS Trust and other trusts to take in MRI images from at least 1,000 patients with a brain tumour – a project called the Brain Tumour Data Accelerator (BTDA). This has kicked off and received Research Ethics Committee approval.

We are not only directly accumulating key data for research use but have also engaged a provider called AIMES to produce a Trusted Research Environment (TRE) to house the data. This will enable researchers to access the data they need to drive advances in treatment and care.

This approach is becoming the industry standard, with the NHS moving to a similar set-up. It allows researchers appropriate access to the data, without the need to transfer the data to their servers, meaning increased security and less chance of data breaches.

Researchers are not allowed to extract the individual data but rather the insights they derive from it, meaning only a single copy of the data is maintained. Once data is available from the BTDA project, it will be taken in to the TRE and made available to researchers.

# OUR NEW RESEARCH FUTURE LEADERS

These five talented scientists and clinicians have been awarded a combined total of over £1.1 million in funding for their innovative research projects, which aim to improve our understanding of brain tumours and develop new treatments.



**Dr Mara De Martino** is investigating the connection between lipid metabolism and immune escape in glioblastoma. Her goal is to identify molecules that promote treatment resistance and develop novel treatments targeting lipid pathways to enhance immunotherapy effectiveness against brain cancers.



**Dr Ola Rominiyi** is researching DNA repair in glioblastoma on a cellular level to identify treatment weaknesses. His work aims to create new treatment strategies with DNA repair inhibitor drugs that are more effective and have fewer side effects.



**Dr Jessica Taylor** is developing a novel strategy called ADCIPs (Antibody-Directed Cytotoxic and Imaging Probes) to identify and treat WNT-medulloblastoma, a highly curable brain tumour in children, without the need for surgery.



**Dr Christopher Mount** is developing a new approach to treat gliomas by engineering immune cells to specifically identify and destroy multiple types of cells within the tumour.



**Dr Angel Alvarez-Prado** is developing a novel therapeutic approach to treat glioblastoma by inhibiting a protein called ADAR1 in combination with TME-targeted immunotherapies, which target cancer cells and their supporting microenvironment.



# BEST CARE EVERYWHERE

Our vision is for everyone affected by a brain tumour, no matter who and where they are, to have access to the same world-class, holistic treatment and support that's right for them. Currently there are gaps and inequalities. So we're growing our support to help more people in an ever-more significant way, we're finding the gaps where people need more support and we're working alongside the community to design and deliver solutions to fill those gaps.

## HIGHLIGHTS OF 2022/23

### MAKING MORE DIFFERENCE

Our services now include our:

- support lines for adults, young adults, children and families
- counselling service
- money and benefits clinic
- online support groups
- events
- podcasts
- printed resources
- website support
- BRIAN app.

86%

said we were able to help them significantly

We've made significant progress this year and here are just some of the highlights:

- Our online support groups grew by 16% to over 28,000 memberships.
- Our individual support grew by 7% to help 9,000 people 12,000 times. And 86% say we were able to help them significantly.

- We helped 339 people through our money and benefit service to find an extra £808k income, averaging £2,400 each.
- We relaunched and simplified our digital support which helps nearly 1 million support seekers with over 500 different pages of brain tumour specific information and support.
- We launched a free, in-house counselling service for all affected adults which helped over 260 people, with 78% reporting a significant improvement to their emotional wellbeing in spite of the ongoing impact of their tumour experience.
- We returned to face-to-face events with 143 guests joining us at family days.
- We have grown podcasts into a major channel with 41 episodes so far.
- People shared 825 more experiences of their diagnosis and treatment through our Improving Brain Tumour Care surveys, to help improve care for everyone.
- We trained over 4,300 more healthcare professionals to recognise the signs and symptoms of a brain tumour and play their part in faster diagnosis.

## WORKING AS A COMMUNITY

Our community is integral to the strategy, design and delivery of our services. When we think about our support team, we don't just think about what we can do as a team of 17 staff, we think about our 43 volunteers, 28,169 online support group members giving and receiving support, 40 champions and over 1,000 others in our Involvement Network, as well as the healthcare professionals and other charities with whom we're partnered to help people. We all work together to discover our community's unmet needs and then fill the gaps, improve healthcare and deliver support.

28,000

memberships of our online support communities

Here are just some examples of how we're doing this:

- We have **community volunteers helping to deliver support** in nearly every role alongside our staff. Forty-three volunteers expand the team by 15%, and their commitment and skill means we can grow and innovate in ways we simply couldn't do without their help.
- We're enabling the **community to support each other**. In our large online support communities, people are giving and receiving support 24/7. We have 14 different groups catering to different needs and experiences, and membership grew by 16% to 28,000 this year, with memberships from over 100 countries.
- Our **podcasts**, which have grown into an important support channel, are developed and delivered by a team including three volunteers, all current or former Involvement Champions and Young Ambassadors. Our podcasts are listened to in 24 countries and are in the top 15% most shared and top 20% most followed!





## FINDING AND FILLING THE GAPS

We enabled people to share their experiences of treatment and care through the Improving Brain Tumour Care surveys and this has resulted in the sharing of 825 diagnosis and treatment experiences from the last two years. The gaps we find feed into our work and the Tessa Jowell Centres of Excellence programme to eliminate healthcare inequalities.

Here are just some of the biggest gaps revealed:

- Diagnosis is slow, hard and poorly supported for too many people. Now 74% go through A&E en route to diagnosis and 46% are first told of their tumour by an A&E doctor not specialised in brain tumours.
- Communication needs to improve – 27% said their prognosis was not explained in a way they understood.
- People still don't have enough professional support and coordination of their care – 43% didn't have good access to a clinical nurse specialist and 70% didn't have a needs assessment and resulting support plan.
- The majority of people have one or more unmet needs, e.g. 58% need more help coping emotionally.
- Access to clinical research trials is too low: only 12% of those surveyed participated in a clinical trial.
- Half of people (55%) strongly recommend their treatment team but a quarter (25%) would not, scoring them 0–6 out of 10.

Engagement in our Improving Brain Tumour Care surveys has helped to grow our Involvement Network to over 1,000 people with diverse backgrounds and experiences. Our involvement programme is how we shape everything we do with the help of our community.

The network and our champion groups help us identify and understand the gaps, design services to fill those gaps and even help deliver the solutions themselves. This way of working permeates our work in research, fundraising, awareness raising, support, campaigning and influencing... everything!

This year, the involvement network has helped shape an 'A to Z' of initiatives from us and others: AI devices for brain activity EEGs (electroencephalograms), bereavement support, the BRIAN app design, counselling, events, our faster diagnosis policy paper, a feelings chart for children, holistic needs assessments, legacy giving campaigns, paediatric information packs, rehab pathways, and research projects on topics ranging from fatigue to glioblastoma outcomes, COVID shielding to immunotherapy, use of the drug dexamethasone to use of aspirin to alleviate cardiovascular risks after tumour diagnoses.

The culmination of this approach has been the co-creation of our charity strategy as a community during the last year. See pages 4–5 for more on this.

### *An example of filling the gaps...*

Having a good holistic needs assessment and resulting personal support plan is critical to people having control of their care and recovering and optimizing their quality of life. Unfortunately we know that this doesn't happen for 70% people. So we decided to develop a brain tumour specific digital tool within our BRIAN app. It is called My Support Plan. It aims to facilitate a more effective and efficient guided conversation about support with your clinical team so you can partner with them and take an active ownership of your support. We have built the tool with the input of clinicians and the community, received great feedback in testing and are now entering pilots with neuroscience centres.

# OUR COUNSELLING SERVICE



**The community said there is a big gap around emotional support, with 58% of people needing more help. We found there was not enough counselling available quickly and accessible to all.**

So, we launched a free counselling service this year which has significantly helped over 260 people with nearly 1,200 sessions, with 94% rating the service very good and outcomes improving by 32%.

We are doubling the service in each of the next two years.

“

I am really grateful for the service. It was something I could depend on when lots of things felt out of my control and gave me a chance to discuss issues important to me at the time.

”

**Feedback from our pilot counselling service**



# VOICES FOR CHANGE

We're committed to empowering everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they're fundraisers or change makers.

## HIGHLIGHTS OF 2022/23

### RELENTLESSLY RAISING FUNDS

This year, in fundraising, we were thrilled to raise £12.7 million. Within this was an incredible £1 million+ in legacies, a record breaking amount for us. We launched a new Gifts in Wills proposition this year and have been receiving many enquiries as a result.

**£12.7M**  
raised

We continued to build our prize-led fundraising stream, with 864 players and 400 winners in our Win Big Lottery so far, and launching our Win Big Raffle in March.

We were pleased to raise over £378,000 in our Spring and Winter Appeals, and also to launch acquisition mailings this year. These have recruited brand new supporters to The Charity, attracting over 200 new financial supporters and raising awareness in 88,000 households with the Better Safe than Tumour campaign leaflets we included in our mailing.

Acquisition of new donors is a key driver of future income and we will be investing in this as we continue to grow The Charity.

Within Community Fundraising, a real highlight was the flourishing of our Supporter Groups, who raised a record-breaking £1 million+ for the first time. We welcomed eight new Supporter Groups, and two existing ones hit major milestones: Lizzie's Fund reaching £500,000 and The Silas Pullen Fund exceeding £800,000.

### COMING TOGETHER WITH THE COMMUNITY

As in-person events resume, our flagship campaign The Twilight Walk was a huge success and we were delighted to return to holding our in-person, Charity-led Twilight Walk event, which this year took place in London. We were also thrilled to see so many people holding their own walks up and down the UK to raise awareness and drive change. See more on page 23.

Another amazing event this year was Everest in the Alps. This gruelling challenge – climbing the height of Everest over four consecutive days in the Alps – was inspired by our former trustee Rob Ritchie, whose five-year-old son Toby was diagnosed with a low-grade tumour and who has vowed to help speed up the search for a cure. Rob and his team raised nearly £400,000, an astonishing amount!

## RAISING VITAL AWARENESS

This year marked the launch of our vitally important Better Safe Than Tumour awareness campaign, intended to raise awareness of the signs and symptoms of a brain tumour in adults and children. We've now reached over 15 million people with the campaign, 146,500 of them going on to access the campaign website and 5,200 completing the symptom checker. On 1 March, for two weeks, our first Better Safe Than Tumour TV advert went live across Sky, Sky VOD, 4OD and ITV Hub to coincide with Brain Tumour Awareness Month, driving over 20,000 people to the website in that time period alone.

**7%**

growth in our social media accounts

Alongside this, we created and printed our new community walking campaign pack, allowing the community to distribute signs and symptoms cards in their communities. So far we've had over 500 requests for packs and this number increases daily.

We were excited to gain 2,234 followers on social media during Brain Tumour Awareness Month this year compared to 1,107 followers last year, and our brand ads generated over 8.5 million impressions, reaching more than 2.5 million accounts. We also secured over 1,100 pieces of coverage, up +64% vs the prior year.

**5,324**

pieces of media coverage





## DRIVING POLICY CHANGE

Our policy work continues to raise awareness, share our Better Safe Than Tumour campaign and push for change among policymakers. We developed and published our *Brain Tumours: Fighting For Faster Diagnosis* report, for which we interviewed GPs, clinicians, nurses, royal colleges, optometrists and researchers, as well as three lived experience focus groups. This year, 30 MPs and parliamentarians across the UK publicly supported the campaign – including a Member of the Senedd who translated the campaign into Welsh.

# 337%

increase in the number of people in our campaigner network

We also responded to the government's 10-Year Cancer Plan for England, helped members of the community submit their own responses, and made a video appeal to the new Secretary of State highlighting the One Cancer Voice coalition petition. This petition encouraged the government to recognise the importance of cancer in their new Major Conditions Strategy (which replaced the 10-Year Cancer Plan).



## TAKING STRIDES TO CHANGE LIVES – THE TWILIGHT WALK 2023



**We were thrilled to see so many people unite to take strides for The Twilight Walk throughout Brain Tumour Awareness Month in March 2023, as well as hold their own walks in October 2022.**

In March, for the first time, we took on The Twilight Walk London, with over 850 members of the community forming a sea of red walkers, passing iconic landmarks such as Big Ben, Buckingham Palace and Hyde Park.

And over 860 people affected by brain tumours took part in 265 Own Walks up and down the country in March 2023 and October 2022, all determined to raise awareness and make a difference for everyone affected by this disease. In total, their efforts raised more than £416,000! This awe-inspiring amount is enough to fund over three and a half years of world-class research into brain tumours.



# MAKE IT COUNT

We're committed to creating and adapting The Charity to best support the delivery of our goals, building a first-class team to utilise our resources, skills and technology in order to maximise our impact as efficiently as possible.

## HIGHLIGHTS OF 2022/23

### GROWING ONCE AGAIN

This was the first full year with the pandemic truly behind us, although its shadow continues to be felt, whether through NHS backlogs for treatment, people living with long Covid symptoms or workplaces adapting to hybrid working. Layered on to this has been the economic story of higher inflation and higher prices driving pressure on the cost of living.

In acknowledging that impact, we find our resolve strengthened and our ambitions for the future brighter than ever. With the co-creation of our new strategy, this year has been about growing back stronger to meet the needs of the community and deliver on our goals. This growth has included our team and volunteers.

Our team has continued to grow from an average of 86 in 2021-22 to 100 in 2022-23. Finding the right people in a competitive recruitment landscape can be difficult but we are delighted that the fantastic culture and rewarding nature of the work has allowed us to do just that. The growth in our team is enabling us to do more, as you will have read in the other sections of this report.

We continued to invest in our people, with the launch of our Management Development programme, to enhance the core skills of our people managers. We are most grateful to Barclays Bank with whom ten members of our team have been matched with external mentors via their Charity

Mentoring Scheme. We have developed and undertaken workshops to embed our new Charity Values, held learning lunches on a wide range of topics and continued our champions groups on culture, sustainability, well-being and equality, diversification and inclusion.

Working in a hybrid way continues to present both opportunities and challenges, opportunities to better engage those working remotely from our office such as our wonderful community fundraisers and the community as well as sometimes saving time and money on travel. The challenges are to ensure we retain our strong culture and to stay effective.

### CELEBRATING OUR VOLUNTEERS

Our volunteers were pivotal to our achievements in 2022-23. We have over 1,000 volunteers across the UK, who so generously lend their time, experience and expertise to support us to achieve our goals.

Our team of volunteers help with everything from fundraising and spreading awareness of the signs and symptoms of a brain tumour in their local communities, to providing professional sports coaching to our London Marathon runners and quality-checking the accuracy of our medical and scientific information.

Most notable this year were our Involvement Champions, who helped co-create our new strategy alongside many others in the community. They worked tirelessly to shape this remarkable blueprint, which we're certain will have an amazing impact in the coming years.

We recruited a further five qualified counsellors and three student placement counsellors to join our support service, reducing the waiting times for this growing and highly valued service. Twelve Charity Ambassadors were appointed in the first phase of our community fundraising team and six search engine optimisation volunteers joined us to optimise our support pages. These are just a few examples of how we have expanded the scope and range of our volunteer programme aided by our Volunteer Coordinator Forums to help us share ideas and co-ordination across The Charity to fully leverage the power of volunteers.

### POWERED BY TECHNOLOGY

The Charity strives to be a digital-first organisation, using the power of technology to reach and help more people and be more effective.

We've invested in updating much of our technology, including rolling out improved back-up systems, enhanced multi-factor authentication, updated hardware and moving to more software-as-a-service.

In addition, we have increased automation, streamlining the transformation and loading of data. These changes help ensure we meet our responsibilities to the community to keep their information safe.

We have also invested in new systems such as Marketing Cloud and deSelect to enhance our communication with our supporters. These tools allow us to tailor our messages to those most relevant and of interest to our supporters.

A new volunteer management system is being rolled and we are currently testing new HR systems.

It is these behind-the-scenes improvements that facilitate the growth in our front-line services and it is why our IT team has grown from two to five people and will grow further. The groundwork we have been laying in investing in technology will allow this growth to continue.



# FINANCE REVIEW

The year to March 2023 was another strong one for The Charity's finances. Despite the mounting pressures on households and business due to the cost of living and inflationary increases, income grew over 10% from last year to hit a new record of £12.7m, exceeding our target of £12.3m. The generosity of the community continues to galvanise us and demonstrates the demand to improve the life and outcomes of those affected by brain tumours.

Expenditure on charitable activities fell year-on-year as a result of a significant multi-year research programme, known as Everest, into paediatric low grade tumours. This world-class programme, which The Charity continues to fund and this year announced a further £5m of funding over five years, has been slower to get fully up to speed and as a result under-spent against the amounts The Charity has previously awarded it. This resulted in The Charity's expenditure on research funding in the year to March 2023 being £1.1m lower than we had planned at the start of the year.

## INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year income was up year-on-year in almost all areas.


In most areas such as Events, Community Fundraising, Supporter Groups and general donations, which represents roughly half our income, income was up between 10% and 20% over 2021-22. This reflects the generosity of the community and the general growth in The Charity as we did more and expanded the number of donors.

We were particularly delighted with the response and participation in our Twilight Walk. Held in London in March it was the first time we have been able to come together in person since the pandemic.

Income from gifts left in legacies, an area The Charity has been working hard to expand, almost doubled from 2021-22 to exceed £1m.

The main area where income was down year-on-year was from Major gifts. This was not a surprise since 2021-22 was an exceptional year having benefitted from £450k to fund a first-of-its-kind clinical trial.

The Charity once again received funding from the Medical Research Council, receiving £540k. The UK Government Covid Medical Research Charity Support Fund was to assist Charities funding medical research impacted by the COVID pandemic.



## EXPENDITURE

Expenditure in the year increased to £11.2m at the Group level.

The Charity's primary objective is to fund quality research and we aim to spend half of our expenditure in this area as it is vital to us achieving our ambitious objectives. Expenditure on Research declined £1.4m, as described in the introduction to the Financial Review, £1.1m of this reduction was due to one research programme running behind schedule and not fully utilising awards made in previous periods.

Patient Support and Campaigning and Awareness expenditure increased by £1.0m year-on-year. £0.4m of the increase was due to a major awareness campaign, Better Safe than Tumour that was launched in the year. The goal of the campaign is to raise public awareness of the signs and symptoms of a brain tumour.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. For The Charity (excluding subsidiaries) we spent 80p in the pound in the year to March 2023 on its charitable objectives.

The largest increase in expenditure, at the Group level, was in Fundraising. Within Fundraising expenditure, £0.8m was in new, wholly owned, trading subsidiaries Acquist Data Holdings Limited, Acquist Data Limited, Medli Health Holding Ltd and Medli Health Ltd.


In 2022 The Charity embarked on a new investment with the primary objective to create a significant new income stream through the commercialisation of the Intellectual Property created within our BRIAN application.

New subsidiary entities were formed to appropriately manage this investment and the related new application development. The Charity funded the investment by way of intercompany loans in line with Charity Commission guidance.

In early 2023 development of the new application and platform, known as Medli, was completed and we were delighted to onboard its first client, Pancreatic Cancer UK.

As a result of slower than anticipated additional client onboarding, Management and the Board of Trustees have taken the decision to minimise any further investment into the Medli application and the related subsidiaries for the foreseeable future. In light of the uncertainty regarding future income opportunities from Medli, and in the interests of prudence, the intercompany loans between The Charity and its subsidiaries have been provided for as a potential bad debt as at 31 March 2023.

The Charity also has a trading subsidiary, TBTC Trading Limited. This subsidiary, which is wholly owned by the Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £12k which will be donated to The Charity.



## INVESTMENTS AND CASH

World stock markets continued to be volatile as they adjusted to the effects of the Russian invasion of Ukraine in February 2022 and to higher lending rates and inflation. At the end of the financial year The Charity's investments were valued

at £13.9m a fall of £0.6m over the previous year, where we had budgeted for a £0.1m growth. All investments are held in highly liquid assets. Current forecasts do not expect the investments to need to be liquidated in the next twelve months as such short-term volatility in values is not considered a significant risk. Cash held as at 31 March 2023 was £4.6m.



## RESERVES POLICY

The level of total Funds at 31 March 2023 was £8.2m, consisting of unrestricted general reserves of £3.9m, designated of £1.7m and restricted of £2.6m. Free reserves, defined as general reserves of £3.9m less functional fixed assets of £0.2m, were £3.7m.

The Charity's interim reserves policy, implemented due to the Covid pandemic, ended in March 2023 and so we have reverted back to the previous policy of maintaining unrestricted reserves in excess of six months' operational costs. As at 31 March 2023, unrestricted reserves, which comprise of General Reserve and Designated Funds totalled £5.7m and annual operational costs were estimated at £9.0 making the actual cover was 7.6 months. The purpose of this policy is to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments.

At 31 March 2023, we had unaccrued but committed research expenditure totalling £10.7m which was subject to the satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2023 (which are all liquid) were £18.4m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

## INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Evelyn Partners have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £13.8m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. The portfolio generated income of £383k and a valuation loss of £859k.

In addition to managed investment funds, the Trustees decided in the year to invest in commercialising the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. The Charity has formed new subsidiaries for this commercial venture and evaluates any investments being made on its financial return against an equivalent asset class.

## EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have over one thousand active volunteers across the UK who support in different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

## RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

1. That we fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.

2. That we are not able to commission enough high-quality research projects. We are developing our engagement with the brain tumour research community, and working to build capacity in the sector. We are also looking at alternative research models. In addition, we have extended funding globally and put significant emphasis on building relationships with key researchers.

3. That we are adversely affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective talent and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.

4. That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

5. That we are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres, and ensure that we have leading edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have cyber insurance policy.

# GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

# OBJECTIVES FOR 2023-24

The Charity objectives remain aligned to its core values and our priority objectives for the year are:

- We will **accelerate cures for all brain tumours**.
- We will **drive the best lifelong care** across the UK, driving up the quality of treatment centres in the UK and empowering our community to share their experiences.
- We will **raise our global voices**, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.

In addition:

- Identifying the best global research to be funded through a new round of Research Grant funding.
- Plan and adapt The Charity so that we can deliver the goals of our new organisational strategy, Living Longer and Better, co-created as a community.

# PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. We are investing time and effort on expanding our fundraising to grow and to provide income for years to come, money that will be used to fund our ambitious year-on-year investment in the best global research.

Our new strategy will guide us from 2023 to 2030 and will set our direction and the shape we need to become in future years.

# THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research and began funding new projects again, as well as raising awareness and supporting thousands of people affected by a brain tumour.

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we cannot thank you enough for continuing to help us as we strive to defeat brain tumours!

In addition to the donors named below, we would like to thank all our anonymous donors.

- ### TRUSTS

BBC Children in Need  
St James's Place Charitable Foundation  
The AOK Trust  
The Colin Oliphant Charitable Trust  
The Lewis Moody Foundation  
The Syncona Foundation  
The Reed Foundation  
The Bert, Aase, Kevin and Jane Trust
- ### FAMILY-LED CHARITY PARTNERS

Angel Child  
James Clifford Campling Trust  
Joss Searchlight  
Nick's Fund  
OSCAR'S Paediatric Brain Tumour Charity  
The Brian Cross Memorial Trust  
The Emily Morris Fund  
The Oli Hilsdon Foundation
- ### CORPORATES

Allports Group  
Atrato Capital Limited  
BECG Group  
Bluecube  
BPL Global  
Business Design Centre  
GlobalLogic  
Gowling WLG  
Hanne & Co Solicitors  
JM Finn  
K&L Gates  
Knight Protection  
Microsoft  
Oddballs Apparel Ltd  
Quirk Solutions  
Salesforce  
Underbelly  
Team Lewis  
Wickes



## CO-FUNDING PARTNERS

Children with Cancer UK  
CRUK  
GOSHCC  
Leeds Hospital Charity

## PATRON

Earl Spencer

## HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE  
Charly Clive  
Dawn French  
Dee Anderson  
Dominic Matteo  
Ella and Matt Mills (Deliciously Ella)  
Guy Opperman MP  
Hal Cruttenden  
Holly Matthews  
Ian Chillcott  
James Jordan  
Jason Durr  
Jess Mills  
Jonny Wilkinson CBE  
Lewis Moody OBE and Annie Moody  
Liam Conlon  
Lorraine Kelly OBE  
Marc Silk  
Matt Allwright  
Mel Giedroyc  
The Neales  
Nick Baines (Peanut – Kaiser Chiefs)  
Nicki Chapman  
Olivia Colman CBE  
Owain Arthur  
Philippa Forrester  
Phil Spencer  
Russell Watson  
Sandy Lyle MBE  
Sherrie Hewson  
Sian Reese-Williams  
Steve Backshall  
Tchéky Karyo  
Tim Burgess and The Charlatans  
Tom Daley  
The Wanted  
Vicki Michelle

## TRUSTEES AND GOVERNANCE

### TRUSTEES

Jack Morris CBE  
Anna Jarvis  
Matimba Swana  
Sukhdip Sandhu  
Jessica Sass (resigned 21/09/23)  
Dr Kieran Palmer  
Hayley Conroy  
Dr Russell Hagan  
Caroline Steel  
Dr Rachel Edgar  
Sean Hird  
Dr Elena Bechberger  
Neil Dickson MBE  
Justine McIlroy  
Dr Alan Palmer  
Simon Hay (resigned 21/09/23)  
Beth Worrall (resigned 02/05/23  
and reappointed 28/07/23)  
Graham Norton (resigned 03/07/22)  
Graham Lindsay (resigned 30/06/22)  
Philippa Murray (resigned 15/09/22)  
Berendina Norton MBE (resigned 15/09/22)

The directors and trustees had liability  
insurance during the financial year.

### CHIEF EXECUTIVE OFFICER

Alex Lochrane (appointed 24/01/2022,  
resigned 01/07/2022)  
Graham Norton (Interim CEO appointed  
04/07/2022, resigned 02/05/2023)  
Graham Lindsay (Deputy-Interim  
CEO appointed 04/07/2022, resigned  
02/05/2023)  
Beth Worrall (Interim CEO appointed  
02/05/2023, resigned 27/07/2023)  
Dr. Michelle Afif (appointed 17/07/2023)

### COMPANY SECRETARY

Liam Heffernan

### CHARITY REGISTRATION NUMBERS

England and Wales 1150054  
Scotland SC045081

## COMPANY NUMBER

08266522

## PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,  
GU51 2UH

## AUDITORS

Menzies LLP Magna House, 18-32 London  
Road, Staines-Upon-Thames, TW18 4BP

## BANKERS

Lloyds Bank Plc, 147 High Street,  
Guildford, GU1 3AG

## INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,  
Stratford-upon-Avon  
Evelyn Partners, 25 Moorgate, London

## RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory  
Board (mentioned on page 34), these are  
just some of the researchers providing an  
ongoing contribution to our success.

Adel Samson  
Alasdair Rooney  
Anthony Byrne  
Anthony Chalmers  
Antoni Michalski  
Chris Jones  
Christopher Mount  
Colin Kennedy  
Colin Watts  
Darren Hargrave  
David Jones  
Diane Puccetti  
Gelareh Zadeh  
Helen Hartley  
Ingela Oberg  
Jessica Taylor  
Kirsty Maddock  
Linda Dirvan  
Linda Sharp  
Louis Chesler  
Lucy Stead  
Mara De Martino  
Marion Smits  
Martin Taphoorn

Melanie Calvert  
Michael Hawkins  
Michael Jenkinson  
Monika Hegi  
Neil Carragher  
Ola Rominiyi  
Pamela Kearns  
Paul Brennan  
Paul Northcott  
Petra Hamerlik  
Philipp Euskirchen  
Pim French  
Rameen Beroukhim  
Richard Gilbertson  
Rohitashwa Sinha  
Sara Melhuish  
Sebastian Brandner  
Simon Bailey  
Simona Parrinello  
Sophie Thomas  
Spencer Watson  
Steve Clifford  
Steve Pollard  
Stuart Smith  
Susan Short  
Thomas Wurdinger  
Todd Hankinson  
Tyler Miller  
Veronica Rendo  
Vincenzo D'Angiolella



BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Richard Gilbertson  
Professor Steve Clifford  
Professor Colin Watts  
Dr Susan Chang  
Professor Simona Parrinello  
Dr Paul Northcott  
Professor Cynthia Hawkins  
Dr Gerry Thompson  
Dr Lucy Stead  
Dr Marcel Kool  
Dr Mark Gilbert  
Dr Omer Bayraktar  
Dr Phedias Diamandis  
Dr Stephen Mack  
Dr Adrienne Boire  
Dr Duane Mitchell

INSTITUTION

The Cambridge Cancer Centre, UK  
The Institute of Child Health, Newcastle University, UK  
University of Birmingham, UK  
University of California San Francisco, USA  
University College London (UCL), UK  
St Jude Children's Research Hospital, USA  
The Hospital for Sick Children, Canada  
University of Edinburgh, UK  
University of Leeds, UK  
German Cancer Research Centre, Germany  
National Institutes of Health (NIH), USA  
The Wellcome Trust Sanger Institute, UK  
University of Toronto, Canada  
St Jude Children's Research Hospital, USA  
Memorial Sloan Kettering Cancer Center, USA  
University of Florida, USA

PAEDIATRIC CLINICAL TRIAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Martin van den Bent  
Dr Matthias Karajannis  
Professor Arzu Onar-Thomas  
Professor Michael Weller  
Professor Jordan Hansford  
Dr Jurgen Lemiere

INSTITUTION

Erasmus MC Cancer Center, Netherlands  
Memorial Sloan Kettering Cancer Center, USA  
St Jude Children's Research Hospital, USA  
University Hospital Zurich, Switzerland  
University of Adelaide, Australia  
KU Leuven, Belgium

LAY ADVISORS

Ms Christina Brincat  
Mrs Deborah Crossan  
Mrs Rachel Rathbone  
Ms Louise Webber-Edwards  
Mr John Graham

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration
- Technology Commercialisation
- Databank (BRIAN)

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details are on the previous page.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward on all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our new research strategy 'Accelerating a Cure' launched in 2021-22 as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical



Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

## APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We used the services of a professional third party fundraiser, Ethicall, during the year in a limited capacity to contact potential new donors. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

## WORKING WITH PARTNERS

We are committed to working with all partners including those in the pharmaceutical and biotech industry in order to meet our objectives. We remain vigilant that our independence is not compromised and we act in the best interests of our community at all times.

## STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including

FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland. Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 17 October 2023 and signed on their behalf by:



**Jack Morris CBE**  
Chair of Trustees

# INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

## OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2023 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2023 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

## BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities section of our report. We are independent of the Group in accordance with the ethical requirements that are

relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

## OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

## MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

## RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

## AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.
- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
  - Posting of fraudulent journal entries
  - Posting of fraudulent payments and receipts in the accounting software
  - Authorisation, processing, and payment of fraudulent expenses
  - Fictitious employees
  - Timing of revenue recognition
- Audit procedures performed by the engagement team included:
  - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
  - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
  - Challenging assumptions and judgments made by management in its significant accounting estimates; and


- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Auditors' report.

## USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



**Janice Matthews**  
FCA (Senior statutory auditor)  
for and on behalf of  
**Menzies LLP**  
Chartered Accountants  
Statutory Auditor  
Magna House  
18-32 London Road  
Staines-Upon-Thames  
TW18 4BP

Date: 17/10/2023



## CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2023

|  | Notes    | Unrestricted<br>Funds<br>£'000 | Restricted<br>Funds<br>£'000 | Total<br>2023<br>£'000 | Unrestricted<br>Funds<br>£'000 | Restricted<br>Funds<br>£'000 | Total<br>2022<br>£'000 |
|--|----------|--------------------------------|------------------------------|------------------------|--------------------------------|------------------------------|------------------------|
| <b>Income and expenditure</b>                                  |          |                                |                              |                        |                                |                              |                        |
| <b>Income from:</b>  |          |                                |                              |                        |                                |                              |                        |
| Donations and legacies   | 3        | 9,456                          | 2,513                        | 11,969                 | 8,681                          | 2,276                        | 10,957                 |
| Other trading  |          | 284                            | 79                           | 363                    | 161                            | 32                           | 193                    |
| Investments  |          | 383                            | -                            | 383                    | 325                            | -                            | 325                    |
| <b>Total income</b>  |          | <b>10,123</b>                  | <b>2,592</b>                 | <b>12,715</b>          | <b>9,167</b>                   | <b>2,308</b>                 | <b>11,475</b>          |
| <b>Expenditure on:</b>   |          |                                |                              |                        |                                |                              |                        |
| Raising funds  |          | 2,892                          | 31                           | 2,923                  | 1,872                          | 1                            | 1,873                  |
| Charitable activities  |          |                                |                              |                        |                                |                              |                        |
| Research   |          | 2,293                          | 2,482                        | 4,775                  | 4,038                          | 2,172                        | 6,210                  |
| Patient support  |          | 1,879                          | 448                          | 2,327                  | 1,394                          | 386                          | 1,780                  |
| Campaigning & raising awareness                                |          | 876                            | 334                          | 1,210                  | 760                            | 2                            | 762                    |
| <b>Total expenditure on charitable activities</b>              |          | <b>5,048</b>                   | <b>3,264</b>                 | <b>8,312</b>           | <b>6,192</b>                   | <b>2,560</b>                 | <b>8,752</b>           |
| <b>Total expenditure</b>                                       | <b>4</b> | <b>7,940</b>                   | <b>3,295</b>                 | <b>11,235</b>          | <b>8,064</b>                   | <b>2,561</b>                 | <b>10,625</b>          |
| <b>Net income before gains and losses on investment assets</b> |          | <b>2,183</b>                   | <b>(703)</b>                 | <b>1,480</b>           | <b>1,103</b>                   | <b>(253)</b>                 | <b>850</b>             |
| Realised and unrealised gains on investment assets             |          | (859)                          | -                            | (859)                  | (97)                           | -                            | (97)                   |
| <b>Net movement in funds for the year</b>                      |          | <b>1,324</b>                   | <b>(703)</b>                 | <b>621</b>             | <b>1,006</b>                   | <b>(253)</b>                 | <b>753</b>             |
| <b>Reconciliation of funds</b>                                 |          |                                |                              |                        |                                |                              |                        |
| Balances at 1 April  |          | 4,354                          | 3,256                        | 7,610                  | 3,348                          | 3,509                        | 6,857                  |
| <b>Balances at 31 March</b>                                    |          | <b>5,678</b>                   | <b>2,553</b>                 | <b>8,231</b>           | <b>4,354</b>                   | <b>3,256</b>                 | <b>7,610</b>           |


The Statement of Financial Activities includes all gains and losses recognised in the year.  
All incoming resources and resources expended derive from continuing activities.  
The notes on pages 43-57 form part of these financial statements

## CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2023

Company number: 08266522

|  | Notes     | Consolidated   |                | Company        |                |
|--|-----------|----------------|----------------|----------------|----------------|
|  |           | 2023<br>£'000  | 2022<br>£'000  | 2023<br>£'000  | 2022<br>£'000  |
| <b>Fixed assets</b>                      |           |                |                |                |                |
| Intangible assets                        | 10        | 7              | 15             | 7              | 15             |
| Tangible assets                          | 11        | 244            | 267            | 244            | 267            |
| Investment in subsidiaries               | 12        | -              | -              | -              | -              |
| Investments                              | 12        | 13,838         | 14,536         | 13,838         | 14,536         |
| <b>Current assets</b>                    |           |                |                |                |                |
| Stock                                    |           | 34             | 6              | -              | -              |
| Debtors                                  | 13        | 1,693          | 820            | 1,572          | 820            |
| Cash at bank                             |           | 4,566          | 5,240          | 4,551          | 5,239          |
|  |           | <b>6,293</b>   | <b>6,066</b>   | <b>6,023</b>   | <b>6,059</b>   |
| <b>Creditors</b>                         |           |                |                |                |                |
| Amounts falling due within one year      | 14        | (12,051)       | (13,174)       | (12,023)       | (13,208)       |
| <b>Net current (liabilities)/ assets</b> |           | <b>(5,758)</b> | <b>(7,108)</b> | <b>(5,990)</b> | <b>(7,149)</b> |
| Provision for liabilities                | 15        | (100)          | (100)          | (100)          | (100)          |
| <b>Net assets</b>                        |           | <b>8,231</b>   | <b>7,610</b>   | <b>8,089</b>   | <b>7,569</b>   |
| <b>Funds</b>                             |           |                |                |                |                |
| General reserve                          |           | 3,985          | 2,662          | 3,843          | 2,621          |
| Designated funds                         |           | 1,693          | 1,692          | 1,693          | 1,692          |
| <b>Unrestricted funds</b>                |           | <b>5,678</b>   | <b>4,354</b>   | <b>5,536</b>   | <b>4,313</b>   |
| Restricted funds                         |           | 2,553          | 3,256          | 2,553          | 3,256          |
|  | <b>19</b> | <b>8,231</b>   | <b>7,610</b>   | <b>8,089</b>   | <b>7,569</b>   |

The financial statements were approved by the trustees on 17 October 2023 and signed on their behalf by:

  
 Jack Morris CBE  
 Chair of Trustees

  
 Neil Dickson MBE  
 Vice-Chair of Trustees

The notes on pages 43-57 form part of these financial statements.

CONSOLIDATED CASH FLOW FOR  
THE YEAR ENDED 31 MARCH 2023

|   | 2023<br>£'000      | 2022<br>£'000                           |                     |                     |
|---|--------------------|---|---------------------|---------------------|
| <b>Net (expenditure) / income for the year<br/>(as per the statement of financial activities)</b> |                    |   |                     |                     |
| <b>Net income for the year</b>  | <b>621</b>         | <b>753</b>                              |                     |                     |
| <b>Adjustments for:</b>   |                    |   |                     |                     |
| Depreciation  | 31                 | 42                                      |                     |                     |
| Losses/ (gains) on investments  | 859                | 97                                      |                     |                     |
| Income from investments   | (383)              | (325)                                   |                     |                     |
| (Increase)/ decrease in stocks  | (27)               | 2                                       |                     |                     |
| Decrease/ (increase) in debtors   | (873)              | (367)                                   |                     |                     |
| Increase / (decrease) in creditors  | (1,123)            | 274                                     |                     |                     |
| <b>Net cash (used in)/ provided by operating activities</b>                                       | <b>(895)</b>       | <b>(72)</b>                             |                     |                     |
| <b>Statement of cash flows</b>  |                    |   |                     |                     |
| <b>Cash flows from operating activities</b>   |                    |   |                     |                     |
| <b>Net cash (used in)/ provided by operating activities</b>                                       | <b>(895)</b>       | <b>(72)</b>                             |                     |                     |
| <b>Cash flows from investing activities:</b>  |                    |   |                     |                     |
| Dividends, interest and rents from investments  | 383                | 325                                     |                     |                     |
| Purchase of property plant & equipment  | -                  | (10)                                    |                     |                     |
| Sale/(purchase) of investments  | (162)              | 19                                      |                     |                     |
| <b>Net cash provided by/ (used in) investing activities</b>                                       | <b>221</b>         | <b>334</b>                              |                     |                     |
| <b>Change in cash and cash equivalents in the year</b>  | (674)              | 262                                     |                     |                     |
| Balances at 1 April   | 5,240              | 4,978                                   |                     |                     |
| <b>Balances at 31 March</b>   | <b>4,566</b>       | <b>5,240</b>                            |                     |                     |
| <b>Analysis of cash and cash equivalents</b>  |                    |   |                     |                     |
| Cash in hand  | 2,544              | 5,240                                   |                     |                     |
| Notice deposits (less than 3 months)  | 2,022              | -                                       |                     |                     |
| <b>Total cash and cash equivalents</b>  | <b>4,566</b>       | <b>5,240</b>                            |                     |                     |
| <b>Analysis of changes in net debt</b>  |                    |   |                     |                     |
|   | At 1 April<br>2022 | Cash from<br>purchase of<br>investments | Other Cash<br>flows | At 31 March<br>2023 |
| Cash  | 5,240              | (162)                                   | (2,534)             | 2,544               |
| Cash equivalents  | -                  | -                                       | 2,022               | 2,022               |
| <b>Net debt</b>   | <b>5,240</b>       | <b>(162)</b>                            | <b>(512)</b>        | <b>4,566</b>        |

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 33. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. ACCOUNTING POLICIES

(a) basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertakings, TBTC Trading Ltd, Acquist Data Holdings Ltd, Acquist Data Ltd, Medli Health Holding Ltd and Medli Health Ltd have been consolidated on a line by line basis.

All Group companies prepare their accounts to 31 March. The results for Acquist Data Holdings Ltd (incorporated 3 March 2022), Acquist Data Ltd (incorporated 3 March 2022), Medli Health Holding Ltd (incorporated 21 September 2022) and Medli Health Ltd (incorporated 22 September 2022) are from their dates of incorporation to 31 March 2023.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £521,000 (2022: outgoing £733,000).

The financial statements have been prepared under the historical cost convention.

**Judgements and key sources of estimation uncertainty**

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

**Significant judgements**

The judgements (apart from those involving estimations) that management has made in the process of applying the entity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

**Key sources of estimation uncertainty**

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.



Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

## **(b) Company status**

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 32. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

## **(c) Income**

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

## **(d) Expenditure**

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

## **(e) Stocks**

Stock is measured at the lower of cost and net realisable value.

## **(f) Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

## **(g) Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

## **(h) Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

|                        |                |
|------------------------|----------------|
| Computer equipment     | 3 years        |
| Office equipment       | 5 years        |
| Leasehold improvements | the lease term |
| Computer software      | 5 years        |

## **(i) Investments**

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

## **(j) Donated assets and services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

## **(k) Operating lease**

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

## **(l) Pensions**

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

## **(m) Financial instruments**

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

## **(n) Going concern**

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. DONATIONS AND LEGACIES

|                                    | Unrestricted<br>£'000 | Restricted<br>£'000 | Total<br>2023<br>£'000 | Unrestricted<br>£'000 | Restricted<br>£'000 | Total<br>2022<br>£'000 |
|------------------------------------|-----------------------|---------------------|------------------------|-----------------------|---------------------|------------------------|
| Ordinary activities:               |                       |                     |                        |                       |                     |                        |
| Regular giving                     | 336                   | 76                  | 412                    | 308                   | 39                  | 347                    |
| Donations, appeals and fundraising | 7,201                 | 1,780               | 8,981                  | 6,756                 | 1,949               | 8,705                  |
| Gift aid                           | 970                   | 47                  | 1,017                  | 815                   | 45                  | 860                    |
| Legacies                           | 949                   | 70                  | 1,019                  | 273                   | 243                 | 516                    |
| Government grants                  | -                     | 540                 | 540                    | 529                   | -                   | 529                    |
|                                    | 9,456                 | 2,513               | 11,969                 | 8,681                 | 2,276               | 10,957                 |

Government grants consist of amounts received under the Government Coronavirus Job Retention Scheme and the COVID Medical Research Charity Support Fund.

4. ANALYSIS OF RESOURCES EXPENDED

|  | Direct Costs<br>£'000 | Grants<br>£'000 | Support<br>Costs<br>£'000 | 2023<br>Total<br>£'000 |
|--|-----------------------|-----------------|---------------------------|------------------------|
| Raising funds                              | 2,678                 | -               | 245                       | 2,923                  |
| Charitable activities:                     |                       |                 |                           |                        |
| Research                                   | 818                   | 3,885           | 72                        | 4,775                  |
| Patient support                            | 2,204                 | -               | 123                       | 2,327                  |
| Campaigning and raising awareness          | 1,104                 | -               | 106                       | 1,210                  |
| Total expenditure on charitable activities | 4,126                 | 3,885           | 301                       | 8,312                  |
| Total expenditure                          | 6,804                 | 3,885           | 546                       | 11,235                 |

|  | Direct Costs<br>£'000 | Grants<br>£'000 | Support<br>Costs<br>£'000 | 2022<br>Total<br>£'000 |
|--|-----------------------|-----------------|---------------------------|------------------------|
| Raising funds                              | 1,721                 | -               | 152                       | 1,873                  |
| Charitable activities:                     |                       |                 |                           |                        |
| Research                                   | 1,086                 | 5,079           | 46                        | 6,210                  |
| Patient support                            | 1,706                 | -               | 74                        | 1,780                  |
| Campaigning and raising awareness          | 675                   | -               | 87                        | 762                    |
| Total expenditure on charitable activities | 3,466                 | 5,079           | 207                       | 8,752                  |
| Total expenditure                          | 5,188                 | 5,079           | 359                       | 10,625                 |

5. RESEARCH GRANT COST ANALYSIS

|                     | 2023<br>£'000 | 2022<br>£'000 |
|---------------------|---------------|---------------|
| Research programmes | 2,002         | 3,640         |
| Research projects   | 961           | 1,145         |
| Clinical trials     | 909           | 299           |
| Conferences         | 13            | (5)           |
|                     | 3,885         | 5,079         |

A breakdown of research costs by individual award is provided in note 21.

6. SUPPORT COSTS BY ACTIVITY

| 2023                              | Finance and<br>human resources<br>£'000 | Central facilities<br>& information<br>technology<br>£'000 | Central<br>management &<br>governance<br>£'000 | Total<br>£'000 |
|-----------------------------------|---|--|--|----------------|
| Raising funds                     | 66                                      | 124  | 55   | 245            |
| Charitable activities:            |   |  |  |                |
| Research                          | 20                                      | 36   | 16   | 72             |
| Patient support                   | 33                                      | 63   | 28   | 124            |
| Campaigning and raising awareness | 29                                      | 53   | 23   | 105            |
| 2023 Total                        | 148                                     | 276  | 122  | 546            |

| 2022                              | Finance and<br>human resources<br>£'000 | Central facilities<br>& information<br>technology<br>£'000 | Central<br>management &<br>governance<br>£'000 | Total<br>£'000 |
|-----------------------------------|---|--|--|----------------|
| Raising funds                     | 44                                      | 69   | 39   | 152            |
| Charitable activities:            |   |  |  |                |
| Research                          | 13                                      | 21   | 12   | 46             |
| Patient support                   | 21                                      | 34   | 19   | 74             |
| Campaigning and raising awareness | 25                                      | 39   | 23   | 87             |
| 2022 Total                        | 103                                     | 163  | 93   | 359            |

Governance costs of £84,000 (2022: £65,000) are included in central management & governance.



7. GOVERNANCE COSTS

|                             | 2023<br>£'000 | 2022<br>£'000 |
|-----------------------------|---------------|---------------|
| Auditor's remuneration      | 27            | 15            |
| Trustee meetings            | 3             | -             |
| Legal and professional fees | 1             | -             |
| Staff                       | 53            | 50            |
|                             | <b>84</b>     | <b>65</b>     |

In addition to Auditor’s remuneration for audit shown above, a further £1,210 was paid for accounting and tax advice. Trustees received no remuneration (2022: £nil). Trustees received no reimbursement for expenses in the year (2022: £nil). The premium in respect of professional liability insurance covering trustee indemnity was £4,511 (2022: £3,759).

8. STAFF COSTS

|  | Group         |               | Company       |               |
|--|---------------|---------------|---------------|---------------|
|  | 2023<br>£'000 | 2022<br>£'000 | 2023<br>£'000 | 2022<br>£'000 |
| Wages and salaries                             | 3,496         | 2,776         | 3,391         | 2,776         |
| Social security costs                          | 335           | 223           | 321           | 223           |
| Payments to defined contribution pension plans | 272           | 223           | 272           | 223           |
|  | <b>4,103</b>  | <b>3,222</b>  | <b>3,984</b>  | <b>3,222</b>  |

During the year redundancy payments were made totalling £3,000 (2022: £nil). At 31 March 2023 there was £nil provided (2022 £nil).

The average number of employees in the Group during the year was 100 (2022: 86).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

|                     | 2023 | 2022 |
|---------------------|------|------|
| £60,001 - £70,000   | -    | 2    |
| £70,001 - £80,000   | 2    | 1    |
| £80,001 - £90,000   | 2    | 1    |
| £90,001 - £100,000  | -    | -    |
| £100,001 - £110,000 | 2    | -    |

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £661,000 (2022: £453,000).

9. TAXATION

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. Subsidiaries in the Group donate any net trading profit to The Brain Tumour Charity and accordingly have no taxable income. No charge to taxation therefore arises.

10. INTANGIBLE FIXED ASSETS

|                                   | Computer Software<br>£'000 |
|-----------------------------------|----------------------------|
| <b>Cost</b>                       |                            |
| At 1 April 2022 and 31 March 2023 | 161                        |
| <b>Depreciation</b>               |                            |
| At 1 April 2022                   | 146                        |
| Charge for the year               | 8                          |
| At 31 March 2023                  | 154                        |
| <b>Net book value</b>             |                            |
| At 31 March 2023                  | 7                          |
| At 31 March 2022                  | 15                         |

11. TANGIBLE FIXED ASSETS

|  | Leasehold<br>Improvements<br>£'000 | Computers<br>and Office<br>Equipment<br>£'000 | <b>Total<br/>£'000</b> |
|--|------------------------------------|---|------------------------|
| <b>Cost</b>                              |                                    |   |                        |
| <b>At 1 April 2022 and 31 March 2023</b> | 292                                | 174   | <b>466</b>             |
| <b>Depreciation</b>                      |                                    |   |                        |
| At 1 April 2022                          | 34                                 | 165   | <b>199</b>             |
| Charge for the year                      | 19                                 | 4   | <b>23</b>              |
| At 31 March 2023                         | 53                                 | 169   | <b>222</b>             |
| <b>Net book value</b>                    |                                    |   |                        |
| At 31 March 2023                         | 239                                | 5   | <b>244</b>             |
| At 31 March 2022                         | 258                                | 9   | <b>267</b>             |

12. INVESTMENTS

(a) Subsidiary Investment

Equity investment in group undertakings

| Cost             | £   |
|------------------|-----|
| At 1 April 2022  | 200 |
| Additions        | 1   |
| At 31 March 2023 | 201 |

The Charity formed two subsidiaries, Medli Health Holding Ltd and Medli Health Ltd on 21 and 22 September 2022 respectively, during the year. The Charity owns 100% of the £1 ordinary share capital of Medli Health Holding Ltd, a company incorporated in England and Wales, company number 14368728. Medli Health Holding Ltd owns 100% of Medli Health Limited, a company incorporated in England and Wales, company number 14371364.

The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holdings Ltd, a company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Ltd owns 100% of the £1 ordinary share capital of Acquist Data Ltd, a company incorporated in England and Wales, company number 13951572.

The purpose of the above companies is to commercialise intellectual property created in developing the BRIAN database, to generate income to be donated to The Charity.

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

The net trading profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

|                          | 2023<br>£'000 | 2022<br>£'000 |
|--------------------------|---------------|---------------|
| Turnover                 | 54            | 59            |
| Cost of sales            | (39)          | (15)          |
| Gross profit             | 15            | 44            |
| Other operating expenses | (3)           | (3)           |
| Profit before donation   | 12            | 41            |
| Donation                 | (41)          | (21)          |
| Retained profit/ (loss)  | (29)          | 20            |

Cost of sales represent cost of stock sold in the year and the cost of fulfilment of orders.

At 31 March 2023 the aggregate assets of TBTC Trading Ltd were £41,000 (2022: £45,000), aggregate liabilities £29,000 (2022: £4,000) and shareholder’s funds £12,000 (2022: £41,000).

The net trading loss of Medli Health Ltd is as set out below.

|                 | 2023<br>£'000 |
|-----------------|---------------|
| Turnover        | 9             |
| Expenditure     | (776)         |
| Retained (loss) | (767)         |

At 31 March 2023 the aggregate assets of Medli Health Ltd were £89,000, aggregate liabilities £856,000 and shareholder’s deficit £767,000.

(b) General investments

Equity investment in group undertakings

|                                      | 2023<br>£'000 | 2022<br>£'000 |
|--------------------------------------|---------------|---------------|
| At 1 April                           | 14,536        | 14,652        |
| Additions at cost                    | 361           | 635           |
| Disposals                            | (290)         | (533)         |
| Net unrealised (loss) on revaluation | (769)         | (218)         |
| At 31 March                          | 13,838        | 14,536        |
| Historical cost                      | 12,298        | 12,306        |

|  | 2023<br>£'000 | 2022<br>£'000 |
|--|---------------|---------------|
| Investments at market value comprised:     |               |               |
| UK equities                                | 3,234         | 3,236         |
| Overseas equities                          | 3,537         | 3,679         |
| Absolute return funds                      | -             | 418           |
| Property                                   | 206           | 124           |
| Multi asset funds                          | 766           | 509           |
| Alternative investments                    | 144           | 287           |
| Fixed income securities                    | 5,834         | 3,421         |
| Cash held within the investment portfolios | 116           | 2,862         |
| Accrued income                             | 1             | -             |
| At 31 March                                | 13,838        | 14,536        |

During the year income from listed investments was £356,000 (2022: £324,000) and interest on deposits £27,000 (2022: £1,000).



13. DEBTORS

|                                 | Consolidated  |               | Company       |               |
|---------------------------------|---------------|---------------|---------------|---------------|
|                                 | 2023<br>£'000 | 2022<br>£'000 | 2023<br>£'000 | 2022<br>£'000 |
| Trade debtors                   | 715           | 373           | 715           | 373           |
| Accrued income and prepayments  | 844           | 446           | 844           | 446           |
| Other debtors                   | 134           | 1             | -             | 1             |
| Amounts owed by Group companies | -             | -             | 13            | -             |
|                                 | <b>1,693</b>  | <b>820</b>    | <b>1,572</b>  | <b>820</b>    |

14. CREDITORS

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2023 £302,000 (2022: £191,000) of income received in the year was deferred and £260,000 (2022: £357,000), brought forward from previous periods, was released.

|                                 | Consolidated  |               | Company       |               |
|---------------------------------|---------------|---------------|---------------|---------------|
|                                 | 2023<br>£'000 | 2022<br>£'000 | 2023<br>£'000 | 2022<br>£'000 |
| Grants payable                  | 11,410        | 12,650        | 11,410        | 12,650        |
| Accruals and deferred income    | 372           | 381           | 366           | 378           |
| Trade creditors                 | 121           | 38            | 111           | 38            |
| Other creditors                 | 67            | 28            | 67            | 28            |
| Social security and other taxes | 81            | 77            | 69            | 76            |
| Amounts owed to Group companies | -             | -             | -             | 38            |
|                                 | <b>12,051</b> | <b>13,174</b> | <b>12,023</b> | <b>13,208</b> |

15. PROVISION FOR LIABILITIES

|                                | Consolidated  |               | Company       |               |
|--------------------------------|---------------|---------------|---------------|---------------|
|                                | 2023<br>£'000 | 2022<br>£'000 | 2023<br>£'000 | 2022<br>£'000 |
| <b>At 1 April and 31 March</b> | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    |

The provision relates to the future cost of obligations under the terms of a property operating lease at Fleet27.

16. RESEARCH COMMITMENTS

At 31 March The Charity had authorised commitments that were subject to outstanding conditions expected to fall due as follows:

|                              | 2023<br>£'000 | 2022<br>£'000 |
|------------------------------|---------------|---------------|
| Within one year              | 3,765         | 3,712         |
| Between one and two years    | 3,101         | 2,768         |
| Between two and three years  | 1,931         | 1,361         |
| Between three and four years | 1,846         | 134           |
| Between four and five years  | 90            | 134           |
| Five years and further       | -             | 145           |
|                              | <b>10,733</b> | <b>8,254</b>  |

The above commitments will be funded from reserves and future income.

17. OPERATING LEASE COMMITMENTS

The total of future minimum lease payments on operating leases are as follows:

| Group and Company                   | On Property   |               | On Equipment  |               |
|-------------------------------------|---------------|---------------|---------------|---------------|
|                                     | 2023<br>£'000 | 2022<br>£'000 | 2023<br>£'000 | 2022<br>£'000 |
| Within one year                     | 216           | 301           | 10            | 18            |
| Between one and five years          | 685           | 1,182         | 38            | 21            |
|                                     | <b>901</b>    | <b>1,483</b>  | <b>48</b>     | <b>39</b>     |
|                                     |               |               |               |               |
| Operating lease charges in the year | 211           | 57            | 15            | 19            |

|                         | Unrestricted<br>Funds<br>£'000 | Restricted<br>Funds<br>£'000 | Total<br>2023<br>£'000 |
|-------------------------|--------------------------------|------------------------------|------------------------|
| 2023                    |                                |                              |                        |
| Intangible fixed assets | 7                              | -                            | 7                      |
| Tangible fixed assets   | 244                            | -                            | 244                    |
| Investments             | 13,838                         | -                            | 13,838                 |
| Other current assets    | 687                            | 5,606                        | 6,293                  |
| Liabilities             | (9,098)                        | (3,053)                      | (12,151)               |
|                         | 5,678                          | 2,553                        | 8,231                  |

| 19. FUNDS                |                             |                                |                                |                            |                              |                              |
|--------------------------|-----------------------------|--------------------------------|--------------------------------|----------------------------|------------------------------|------------------------------|
| Consolidated<br>2023     | At 1 April<br>2022<br>£'000 | Incoming<br>resources<br>£'000 | Resources<br>expended<br>£'000 | Fund<br>transfers<br>£'000 | Investment<br>gains<br>£'000 | At 31 March<br>2023<br>£'000 |
| <b>Restricted funds:</b> |                             |                                |                                |                            |                              |                              |
| Research funds           | 2,198                       | 1,482                          | (2,682)                        | 171                        | -                            | <b>1,169</b>                 |
| Everest fund             | -                           | 545                            | 200                            | -                          | -                            | <b>745</b>                   |

| <b>Consolidated<br/>2023</b> | At 1 April<br>2022<br>£'000 | Incoming<br>resources<br>£'000 | Resources<br>expended<br>£'000 | Fund<br>transfers<br>£'000 | Investment<br>gains<br>£'000 | <b>At 31 March<br/>2023<br/>£'000</b> |
|------------------------------|-----------------------------|--------------------------------|--------------------------------|----------------------------|------------------------------|---------------------------------------|
| <b>Restricted funds:</b>     |                             |                                |                                |                            |                              |                                       |
| Research funds               | 2,198                       | 1,482                          | (2,682)                        | 171                        | -                            | <b>1,169</b>                          |
| Everest fund                 | -                           | 545                            | 200                            | -                          | -                            | <b>745</b>                            |
| Awareness funds              | 382                         | 114                            | (337)                          | -                          | -                            | <b>159</b>                            |
| Support funds                | 675                         | 451                            | (475)                          | (171)                      | -                            | <b>480</b>                            |
|                              | <b>3,256</b>                | <b>2,592</b>                   | <b>(3,295)</b>                 | <b>-</b>                   | <b>-</b>                     | <b>2,553</b>                          |
| <b>Unrestricted funds:</b>   |                             |                                |                                |                            |                              |                                       |
| General reserve              | 2,662                       | 9,302                          | (7,120)                        | -                          | (859)                        | <b>3,985</b>                          |
| Designated funds             | 1,692                       | 821                            | (820)                          | -                          | -                            | <b>1,693</b>                          |
|                              | 4,354                       | 10,123                         | (7,940)                        | -                          | (859)                        | <b>5,678</b>                          |
|                              | <b>7,610</b>                | <b>12,715</b>                  | <b>(11,235)</b>                | <b>-</b>                   | <b>(859)</b>                 | <b>8,231</b>                          |

| <b>Consolidated<br/>2022</b> | At 1 April<br>2021<br>£'000 | Incoming<br>resources<br>£'000 | Resources<br>expended<br>£'000 | Fund<br>transfers<br>£'000 | Investment<br>gains<br>£'000 | At 31 March<br>2022<br>£'000 |
|------------------------------|-----------------------------|--------------------------------|--------------------------------|----------------------------|------------------------------|------------------------------|
| <b>Restricted funds:</b>     |                             |                                |                                |                            | -                            |                              |
| Research funds               | 2,056                       | 1,637                          | (1,495)                        | -                          | -                            | 2,198                        |
| Everest fund                 | 486                         | 191                            | (677)                          | -                          | -                            | -                            |
| Awareness funds              | 383                         | 2                              | (3)                            | -                          | -                            | 382                          |
| Support funds                | 584                         | 478                            | (387)                          | -                          | -                            | 675                          |

| Company<br>2022          | At 1 April<br>2021<br>£'000 | Incoming<br>resources<br>£'000 | Resources<br>expended<br>£'000 | Fund<br>transfers<br>£'000 | Investment<br>gains<br>£'000 | At 31 March<br>2022<br>£'000 |
|--------------------------|-----------------------------|--------------------------------|--------------------------------|----------------------------|------------------------------|------------------------------|
| <b>Restricted funds:</b> |                             |                                |                                |                            |                              |                              |
| Research funds           | 2,056                       | 1,637                          | (1,495)                        | -                          | -                            | 2,198                        |
| Everest fund             | 486                         | 191                            | (677)                          | -                          | -                            | -                            |
| Awareness funds          | 383                         | 2                              | (3)                            | -                          | -                            | 382                          |
| Support funds            | 584                         | 478                            | (387)                          | -                          | -                            | 675                          |

**55** The Brain Tumour Charity Annual Report and Accounts 2022-2023



PURPOSE OF RESTRICTED FUNDS

|                 |  |
|-----------------|--|
| Research funds  | Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 21.  |
| Everest fund    | During 2015/16 we received exceptional income of £2,890,000 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.                       |
| Awareness funds | Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is Better Safe Than Tumour.  |
| Support funds   | Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected. |

Designated funds represent accumulated net income raised by our supporters where they have expressed a preference over how the funds they raise should be spent. Preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. RELATED PARTIES

|   |   |
|---|---|
| The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2023 The Charity was owed £24,000 from TBTC Trading Ltd (2022: £38,000 owed to TBTC Trading Ltd).  | <ul style="list-style-type: none"><li>• Was owed £nil from Acquist Data Holdings Ltd (2022: owed £100)</li><li>• Was owed £199 (2022: £nil) from Medli Health Holding Ltd</li><li>• Was owed £400,000 from Acquist Data Ltd in the form of an intercompany loan bearing interest at 3% above Bank of England base rate.</li><li>• Was owed £500,000 from Medli Health Ltd in the form of an intercompany loan bearing interest at 3% above Bank of England base rate and owed Medli Health Ltd £10,282 on an intercompany balance</li></ul> |
| The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited.   |   |
| The Charity owns 1 of the issued £1 ordinary shares of Medli Health Holding Limited, a company with the same registered address as The Charity. Medli Health Holding Limited wholly owns the share capital of Medli Health Limited.   | The Charity has created a bad dept provision in full for the intercompany loans payable by Acquist Data Ltd and Medli Health Ltd.   |
| Acquist Data Limited was formed to commercialise the intellectual property developed by The Charity in creating its BRIAN app and database. During the year The Charity formed a new company, Medli Health Ltd to replace Acquist Data Ltd as a trading entity and Acquist transferred to Medli Health Ltd the costs it had incurred. At 31 March 2023 The Charity: | At 31 March 2023 Medli Health Ltd owed Acquist Data Ltd £345,958.   |
|   | Trustees, their close family members and entities they control, made donations to The Charity totalling £36,536 during the year (2022: £41,336) and paid contributions totalling £65 (2022: £381) during a number of our fundraising events.  |

21. RESEARCH AWARDS

|   | 2023<br>£'000 | 2022<br>£'000 |
|---|---------------|---------------|
| Programme - Chesler - ICR - Medullo super enhancers   | -             | 308           |
| Programme - Jones - DKFZ - Everest Centre   | (200)         | 914           |
| Programme - Kennedy - University Southampton - PNET5 QoL  | 46            | 45            |
| Programme - Zadeh - University Health Network - Clinically aggressive meningiomas                           | -             | 130           |
| Programme - Northcott - St Judes - MERIT  | 243           | 131           |
| Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma                              | 142           | 267           |
| Programme - Parrinello - UCL - Mapping spatio-temporal heterogenity   | 374           | 357           |
| Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC                                | 302           | 299           |
| Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM                              | 479           | 564           |
| Programme - Quest for Cures 2019 - Chesler ICR  | 292           | 296           |
| Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber  | 324           | 329           |
| <b>Total Programmes</b>   | <b>2,002</b>  | <b>3,640</b>  |
| Project - Jones - ICR - Gene editing for DIPG - Billie Butterfly fund                                       | (4)           | -             |
| Project - Sharp - Newcastle University - Self-supporting management for survivors                           | -             | 111           |
| Project - Northcott - St Judes - Refining medullo in USA clinical trials                                    | -             | 100           |
| Project - Hawkins - Uni Birmingham - Combining child and young adult data for better monitoring             | -             | 18            |
| Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people                              | 83            | 82            |
| Project - Hegi - Lausanne - MGMT methylation  | -             | 42            |
| Project - Rominiyi - Sheffield - Ex-vivo 3D models  | -             | 60            |
| Project - Clinical Biomarkers 2019/2 - Zadeh - UHN  | 99            | 207           |
| Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital  | 96            | 96            |
| Project - Expanding Theories 2019/2 - French - Erasmus  | -             | 60            |
| Project - Expanding Theories 2019/2 - Brandner - UCL  | -             | 58            |
| Project - Future Leaders 2019 - Croal - Nottingham  | 66            | 66            |
| Project - Future Leaders 2019 - Watson - Lausanne   | 60            | 60            |
| Project - Future Leaders 2019 - Miller - Massachusetts  | 60            | 60            |
| Project - Future Leaders 2019 - Rendo - Dana-Farber   | 60            | 60            |
| Project - Future Leaders 2022/3 - De Martino - New York   | 74            | -             |
| Project - Future Leaders 2022/3 - Taylor - Cambridge  | 67            | -             |
| Project - Future Leaders 2022/3 - Mount - Harvard Masschusetts - Enhancing CAR-T cell therapies for gliomas | 75            | -             |
| Project - Future Leaders 2022/3 - Rominiyi - Sheffield  | 75            | -             |
| Project - Future Leaders 2022/3 - Alvarez-Prado - Lausanne  | 75            | -             |
| Project - Future Leaders 2022/3 - Vinel - London  | 75            | -             |
| Project - Quality of Life 2019 - Byrne - Cardiff  | -             | 65            |
| <b>Total Projects</b>   | <b>961</b>    | <b>1,145</b>  |
| Clinical Trial - Watts - Birmingham - BRAIN-MATRIX  | 582           | -             |
| Clinical Trial - Kearns - University Birmingham - PNET5 CTU   | 44            | 44            |
| Clinical Trial - HR-MB - Bailey - Newcastle   | 89            | 109           |
| Clinical Trial - ARISTOCRAT - Short - Leeds   | 194           | 146           |
| <b>Total Clinical Trials</b>  | <b>909</b>    | <b>299</b>    |
| Conferences, workshops and other  | 13            | (5)           |
|   | <b>3,885</b>  | <b>5,079</b>  |

**[thebraintumourcharity.org](https://thebraintumourcharity.org)**

Registered office: Fleet 27, Rye Close,  
Fleet, Hampshire, GU51 2UH  
© The Brain Tumour Charity 2023.  
Registered Charity in England and  
Wales (1150054) and Scotland (SC045081).

The logo for The Brain Tumour Charity is displayed on a white, rounded rectangular background. It features the words "THE BRAIN TUMOUR CHARITY" in a bold, black, sans-serif font. The word "THE" is positioned above "BRAIN". The word "TUMOUR" is on the same line as "BRAIN", with a red exclamation mark replacing the letter "I". The word "CHARITY" is positioned below "TUMOUR".

**THE  
BRAIN  
TUMOUR  
CHARITY**